跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LR-1
首页
药物
LR-1
LR-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Development and application of microcystic toxin beta-type anti-idiotype nano antibody
申请人: UNIV NANCHANG
优先权: 2024
CN
Laminin receptor gene Cq-LR for recognition and combination of WSSV and its preparation method and application
申请人: UNIV XIAMEN
优先权: 2017
CN
Anti-microcystic toxin-LR nano antibody and application thereof
申请人: UNIV NANCHANG
优先权: 2026
CN
Microcystin monoclonal antibody and its preparation method and application
申请人: UNIV TSINGHUA
优先权: 2007
CN
Microcystic toxin alpha-type anti-idiotype nano antibody and application thereof
申请人: UNIV NANCHANG
优先权: 2024
CN
Antibacterial peptide LR for resisting mycobacterium tuberculosis as well as preparation method and application of antibacterial peptide LR
申请人: UNIV NANJING AGRICULTURAL
优先权: 2015
CN
Bifidobacterium breve LR-T188 for promoting skeletal development and application thereof
申请人: TONGBOSHI HEALTH IND HEBEI CO LTD
优先权: 2025
CN
Lactobacillus rhamnosus LR-C111 helpful for skin aging resistance and application of lactobacillus rhamnosus LR-C111
申请人: ZHONGCHUANG YIKE SHENYANG BIOTECHNOLOGY RES CO LTD
优先权: 2025
CN
药物
反馈